Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $20,825.61 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $26.13, for a total value of $20,825.61. Following the sale, the director owned 23,884 shares of the company’s stock, valued at $624,088.92. The trade was a 3.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Up 1.1%

NYSEAMERICAN:PTHS traded up $0.27 on Tuesday, hitting $24.60. 36,589 shares of the company’s stock traded hands, compared to its average volume of 15,341. The firm has a market capitalization of $85.61 million, a P/E ratio of -1.19 and a beta of 3.10. Pelthos Therapeutics Inc. has a 1 year low of $16.09 and a 1 year high of $37.50. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79. The firm’s 50-day simple moving average is $26.73.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The company had revenue of $10.91 million for the quarter. On average, research analysts forecast that Pelthos Therapeutics Inc. will post -12.63 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on PTHS shares. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Oppenheimer lifted their price objective on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Cantor Fitzgerald initiated coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.80.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after purchasing an additional 3,295 shares during the last quarter. Knott David M Jr raised its holdings in Pelthos Therapeutics by 215.5% during the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after buying an additional 13,169 shares in the last quarter. Persistent Asset Partners Ltd raised its holdings in Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after buying an additional 3,604 shares in the last quarter. Diadema Partners LP lifted its position in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after buying an additional 14,502 shares during the last quarter. Finally, Cantor Fitzgerald L. P. bought a new stake in shares of Pelthos Therapeutics during the 4th quarter worth about $1,085,000. Institutional investors and hedge funds own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).